Definium Therapeutics Cash Reserves Increase to $411.6 Million
As of December 31, 2025, Definium Therapeutics had cash, cash equivalents and investments of $411.6 million compared to $273.7 million as of December 31, 2024. Based on the Company's current operating plan and anticipated milestones, the Company believes that its cash, cash equivalents and investments as of December 31, 2025 will be sufficient to fund the Company's operations into 2028.
